The nation of Zimbabwe has declined a major US health deal worth 367 million US dollars (272 million pounds) over five years over the United States' request for confidential information.
This rejection was revealed after a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "lopsided".
A government spokesperson has since stated that the United States was requesting biological samples for research and commercial gain but was unwilling to share the benefits from any future treatments.
"We must now begin the difficult and regrettable task of scaling back our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for more dialogue to secure a deal suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Implications
This development follows a comparable case in neighbouring Kenya, where a court halted a similar deal with the US after legal challenges were filed about the security of Kenyans' medical information.
After resuming office last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
The agency had managed assistance for the American government, but Trump claimed its spending was "wasteful" and his administration was seeking direct bilateral deals to enhance transparency and accountability.
As per reports, Sixteen nations in Africa have to date signed these new health pacts, representing more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, without any equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our country would provide the raw materials for scientific discovery with no assurance that the resulting innovations would be accessible to our citizens should a future pandemic arise."
National Interest and International Frameworks
He also said that the American exit from the global health body and its push of bilateral deals were disrupting structures previously established via the global organization.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This framework is designed to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the resources to create them."
These objections over the US deal "are not meant as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our American counterparts on how future collaboration might be structured in a manner that respects the independence and interests of both nations."
Health Experts Response
Medical experts stated it acknowledged the government's concerns, but suggested that talks must proceed given that a large portion of the country's HIV programmes relied on foreign aid.
"If specific concerns arise, including those relating to information security or agreement terms, these can often be addressed through detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the complex debate between accepting vital foreign assistance and protecting local interests in an increasingly data-driven world.